ExpiresMay 4, 2021
Oregon Health & Science University School of Medicine
With regard to buprenorphine, there remains a significant gap between need and availability in all of our target populations. There is also a significant gap between the number of DATA-waived physicians in Oregon (as derived from DEA license review) and those who are actively prescribing buprenorphine (as derived from the Oregon Prescription Drug Monitoring Database). Between January and March 2016, only 30% of DATA-waived physicians wrote a prescription for buprenorphine. In addition, we know that primary care clinicians need additional support to have the confidence to begin treating opioid use disorder and other substance use disorders in the primary care setting. These programs seek to build the knowledge, confidence, and abilities of primary care clinicians to diagnose and treat this high need population.
ABMS Member Board Approvals by Type
ABMS MOC Part II CME Activity
Psychiatry and Neurology
NOTE: If a Member Board has not deemed this activity for MOC approval as an accredited CME activity, this activity may count toward an ABMS Member Board’s general CME requirement. Please refer directly to your Member Board’s MOC Part II Lifelong Learning and Self-Assessment Program Requirements.
Chronic Pain and Opioids Program Learning Objectives
1. Understand and assess different types of pain
2. Develop an approach for appropriate and ethical treatment plans for patients with opioid use disorder 3. Discuss evidence-based behavioral interventions for persistent pain
4. Learn techniques to manage opioid tapers
5. Discuss Buprenorphine induction through case discussion and guided mentoring
Interpersonal & Communication Skills, Medical Knowledge, Patient Care & Procedural Skills, Practice-based Learning & Improvement, Systems-based Practice
CME Credit Type
AMA PRA Category 1 Credit
Inpatient, Outpatient, Urban, VA/Military